{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"6403.13","value":"32318.69"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"Day 1: pre-dose (n=8, 0, 0)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"761.37","value":"4064.37"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"Day 1: 2 hour (n=8, 0, 0)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"555.71","value":"939.83"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"Day 2: pre-dose (n=8, 0, 0)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"303.64","value":"526.49"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"Day 4: pre-dose (n=7, 0, 0)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"173.19","value":"456.28"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"Day 5: pre-dose (n=8, 0, 0)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"232.88","value":"506.16"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"Day 5: 30 min (n=7, 0, 0)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"174.85","value":"458.72"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"Day 5: 1 hour (n=8, 0, 0)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"160.56","value":"449.03"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"Day 5: 2 hour (n=7, 0, 0)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"101.67","value":"366.31"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"Day 5: 3 hour (n=8, 0, 0)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"115.59","value":"347.81"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"Day 5: 4 hour (n=7, 0, 0)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"72.97","value":"264.79"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"Day 5: 6 hour (n=8, 0, 0)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"301.64","value":"508.32"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"Day 7: pre-dose (n=8, 0, 0)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"6252.46","value":"33320.64"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"Day 21 (n=8, 0, 0)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"description":"Blood samples were collected at specified time points for GSK3039294. Pharmacodynamic (PD) population consist of all participants who received at least one dose of study medication and who also had a baseline measurement and at least one post-treatment PD measure.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received GSK3039294 600 mg, capsules, orally, under fed condition, QD for 7 days in cohort 3.","id":"OG000","title":"Part B: Cohort 3- GSK3039294 600 mg QD"},{"description":"Participants were planned to receive repeat dose of GSK3039294 for 21 days in cohort 4a. The dose level was to be adjusted once during the 21 days. Cohort 4a was not initiated due to safety reasons during conduct of Part B (Cohort 3).","id":"OG001","title":"Part B: Cohort 4a- GSK3039294"},{"description":"Participants were planned to receive repeat dose of GSK3039294 for 21 days in cohort 4b. The dose level was to be adjusted once during the 21 days. Cohort 4b was not initiated due to safety reasons during conduct of Part B (Cohort 3).","id":"OG002","title":"Part B: Cohort 4b- GSK3039294"}],"paramType":"MEAN","populationDescription":"PD population. Data was not collected as study was terminated, due to safety reasons during conduct of Part B (end of Cohort 3) whereas Cohort 4a and 4b were not recruited in Part B. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).","reportingStatus":"POSTED","timeFrame":"Cohort 3:Days1(pre-dose, 2hour post-dose),2(pre-dose),4(pre-dose),5(pre-dose, 30min,1,2,3,4,6 hours post-dose),7(pre-dose)and 21post-dose;Cohort4:Days1(pre-dose, 2 hour post-dose),2(pre-dose),4(pre-dose), 5(pre-dose, and 2 hours post-dose) and 35post-dose","title":"Part B: Plasma Serum Amyloid P Component (SAP) Level of GSK3039294","type":"SECONDARY","unitOfMeasure":"ng/mL"}